Results 91 to 100 of about 8,252,790 (324)

No clear timeline for approval of cannabis-based painkiller in Ireland.

open access: yes, 2012
The Department of Health is still exploring how a cannabis-based painkiller could be legally prescribed for use in Ireland amid increasing approval for the drug’s availability in the EU.

core  

Drug updates and approvals

open access: yesThe Nurse Practitioner, 2019
Abstract: In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol (Duaklir ...
Lauren Hartsell, Crump   +7 more
openaire   +3 more sources

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

open access: yesFEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

New Serious Safety Warnings for Targeted Anticancer Agents After Their Initial FDA Approval

open access: yes
Background: New safety concerns about targeted anticancer agents (TAAs) often emerge in the first few years after their initial regulatory approval. Our aim was to determine whether new serious and potentially fatal adverse drug reactions (ADRs) continue
Dimitar Stefanovski   +3 more
core   +1 more source

The Drug Approval Process and the Information it Provides

open access: yes, 1987
By law, the commissioner of the Food and Drug Administration (FDA) is responsible for determining whether a new drug is safe and efficacious before it is approved for marketing in the U.S. and for monitoring its use after approval. This paper provides a
Hugh H. Tilson   +4 more
core   +1 more source

ClinicalTrials.gov and Drugs@FDA: A comparison of results reporting for new drug approval trials

open access: yesAnnals of Internal Medicine, 2016
Sponsors are required by federal law to submit summary results of applicable clinical trials (including those beyond phase 1 supporting U.S. Food and Drug Administration [FDA] new drug approvals) to ClinicalTrials.gov for public posting (1).
Lisa M. Schwartz   +4 more
semanticscholar   +1 more source

Salmonella lipopolysaccharide‐containing supported lipid bilayers as platforms to study bacteriophage interactions

open access: yesFEBS Letters, EarlyView.
We present robust protocols for the preparation of supported lipid bilayers (SLBs) incorporating either Salmonella smooth LPS or outer membrane vesicles (OMVs). We use a combination of quartz crystal microbalance with dissipation (QCM‐D) and fluorescence microscopy to both characterize the SLBs of various compositions and to probe their interactions ...
Hudson P. Pace   +6 more
wiley   +1 more source

Investigating transcription factor dynamics in health and disease using FRAP

open access: yesFEBS Letters, EarlyView.
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj   +3 more
wiley   +1 more source

Drug Approval-Patent Linkage System in the US and Canada

open access: yes, 2008
- Drug approval-patent linkage is the practice of linking drug marketing approval to the patent status of the originator's product and not allowing the grant of marketing approval to any third party prior to the expiration of the patent term unless by ...
박실비아
core  

Home - About - Disclaimer - Privacy